Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

With the approval, Medtronic (MDT) aims to strengthen its Cardiac and Vascular Group business globally.

Medtronic (MDT) Gets Canada Nod for Micra AV to Treat AV Block

We think that 3M currently is a better pick compared to Medtronic. 3M trades at about 3.1x trailing Revenues, compared to over 5.4x for Medtronic, though both belong to different industry groups.

3M Stock Can Offer Better Gains Compared To Medtronic

Medtronic's (MDT) OsteoCool RFA System is expected to provide better relief from debilitating pain for cancer patients.

Medtronic (MDT) Releases Positive Study Results of RFA Therapy

Medtronic PLC (NYSE: MDT) is well-positioned for a COVID-19 recovery and has upside to the consensus estimates for fiscal 2022, according to Morgan Stanley. The Medtronic Analyst: David Lewis upgraded Medtronic from Equal-Weight to Overweight and raised the price target from $120 to $140.

Morgan Stanley Upgrades Medtronic On Exposure To COVID-19 Recovery

Broadcom

Bristol-Myers

Goldman Sachs

With 2020 rapidly and thankfully coming to a close, many investors are evaluating portfolios for 2021.

5 BofA Securities US 1 Stocks to Buy Pay a Higher Dividend Than the S&P 500

DUBLIN, Dec. 15, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT) today announced the release of outcomes in the first 100 patients treated with the OsteoCool™ Radiofrequency Ablation (RFA) System in the OPuS One Clinical Study (as referenced below) – the largest, prospective study in RFA...

Medtronic's OsteoCool™ Procedure Shows Significant, Swift Pain Relief and Sustained Improvement for Cancer Patients

DUBLIN, Dec. 14, 2020 /PRNewswire/ -- Medtronic plc (NYSE:MDT) announced today that Sean Salmon, Executive Vice President and President, Diabetes Operating Unit has been named Executive Vice President and President, Cardiovascular Portfolio effective January 1. Salmon will also continue...

Sean Salmon Named EVP & President Cardiovascular Portfolio; Continues as EVP & President Diabetes Operating Unit

Medtronic plc (MDT) 2020 Annual Meeting Conference (Transcript)

Medtronic's (MDT) Carpediem CRRT system compares favorably with the traditional three times a week therapy session.

Medtronic (MDT) Carpediem to Tap Pediatric Kidney Care Market

Carrier Global

Trane Technologies plc

Abbott Labs

Boston Scientific

Last month, the stock market responded positively to the news of a potential Covid-19 vaccine. While the initial impact of the news appears to be dissipating, now may be the right time to look at stocks that could fundamentally benefit from potential sales related to the vaccine.

Is It Time to Pounce on Covid Vaccine Stocks?

General Dynamics

Altria

NextEra Energy

Tyson Foods

This article is part of our monthly series where we highlight five companies that are large cap, relatively safe, dividend paying, and are offering large discounts to their historical norms. It's always a good idea to keep your wish list ready by separating the wheat from the chaff.

5 Safe And Cheap Dividend Stocks To Invest In (December 2020)

Amgen

Healthpeak Properties

Glenview Capital Management recently disclosed its portfolio updates for the third quarter of 2020, which ended on Sept. 30.

The Top New Health Care Buys of Larry Robbins' Firm

Medtronic's (MDT) Management Presents at Piper Sandler 32nd Annual Virtual Healthcare Conference (Transcript)

DUBLIN, Dec. 1, 2020 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate virtually in the Evercore ISI 3rd Annual HealthCONx Conference on Thursday, December 3, 2020. Mike Weinstein, senior vice president of strategy for...

Medtronic SVP of Strategy Mike Weinstein to Speak at Evercore ISI Healthcare Conference

Align Technology

Among several domains within the MedTech space, several pediatric medical device stocks have been gaining traction amid the coronavirus pandemic

Pediatric Medical Space Thrives Amid COVID-19: 3 Stocks in Focus

We believe that Medtronic stock is a good buying opportunity at the present time. MDT stock trades near $115 currently and it is, in fact, down 6% from its pre-Covid high of $121 in February 2020 – just before the coronavirus pandemic hit the world.

Further Upside For Medtronic Stock

DUBLIN, Nov. 30, 2020 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate virtually in the Piper Sandler 32nd Annual Healthcare Conference on Wednesday, December 2, 2020. Mike Coyle, executive vice president and president...

Medtronic EVP & President of Cardiovascular Portfolio Mike Coyle to Speak at Piper Sandler Healthcare Conference

DUBLIN and MINNEAPOLIS, Nov. 30, 2020 /PRNewswire/ -- With the pandemic surging across the globe and food insecurity on the rise, Medtronic and the Medtronic Foundation today announced an additional $3.8 million commitment to provide healthcare worker support and protection, mental health...

Medtronic and the Medtronic Foundation Expand COVID-19 Support to More Than $46 Million USD

Based on the ongoing strong recovery in sales, Medtronic (MDT) expects fiscal third-quarter MITG growth to be in the low single digits.

Medtronic (MDT) Shows Strong Sales Recovery Amid COVID-19 Crisis

Mastercard

Thermo Fisher Scientific

The S&P 500 saw its trailing 12-month real earnings per share (EPS) grow by approximately 1.4% on average every year over the past five years. The index's share price ($3,629.65 as of Wednesday) rose by nearly 74% over the past five years through Nov. 25.

This Trio Is Growing Earnings Fast

Medtronic PLC's (MDT) CEO Geoffrey Martha on Q2 2021 Results - Earnings Call Transcript

Deferred procedures due to the pandemic impact Medtronic's (MDT) Q2 performance.

Medtronic's (MDT) Q2 Earnings Beat Estimates, Margins Fall

Shares of Medtronic (NYSE:MDT) rose 0.2% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 22.14% over the past year to $1.02, which beat the estimate of $0.80.

Medtronic: Q2 Earnings Insights

Medtronic (MDT) delivered earnings and revenue surprises of 30.77% and 8.51%, respectively, for the quarter ended October 2020. Do the numbers hold clues to what lies ahead for the stock?

Medtronic (MDT) Tops Q2 Earnings and Revenue Estimates

Medtronic earnings and sales beat fiscal Q2 estimates. Shares of the medical products giant rose slightly, near a prior buy point.

News for Medtronic Stock (MDT)